Genotyping Array Sales Push Affymetrix's Q2 Revenues up 7 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Affymetrix said after the close of the market on Thursday that its second quarter revenues climbed 7 percent year over year.

The Santa Clara, Calif.-based microarray firm said that for the three months ended June 30, total revenues increased to $85.4 million from $79.5 million a year ago, beating the average Wall Street estimate of $83.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.